Evaxion A/S 6-K/A, filed Jun 8, 2022
Evaxion A/S (EVAX)
About this 6-K/A
Evaxion A/S filed this 6-K/A on June 8, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2022
Commission File Number: 001-39950
Evaxion Biotech A/S
(Exact Name of Registrant as Specified in Its Charter)
Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXPLANATORY NOTE
This Amendment to the Report on Form 6-K, originally filed with the Securities and Exchange Commission on June 7, 2022 (the “Form 6-K”), is being filed solely for the purposes of providing that (i) certain conditions to which LPC’s (as defined in Form 6-K) obligation to purchase ADSs is subject include that a registration statement registering the resale of the Shares under the Securities Act of 1933, as amended, is declared effective by the Securities and Exchange Commission, and that a final prospectus relating thereto is filed with the SEC; and (ii) the Company has opted to pay the commitment fee by issuing LPC 428,572 ordinary shares.
Other than as expressly set forth above, this Form 6-K/A does not, and does not purport to, amend, update or restate the information in any other item of the Form 6-K, or reflect any events that have occurred after the Form 6-K was originally filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Evaxion Biotech A/S | ||
| Date: June 8, 2022 | By: | /s/ Lori Hollander |
| Lori Hollander | ||
| Vice President, Financial Planning & Analysis | ||